ImmUnion started with the development of SARS-CoV-2 ImmunoJunction for the passive vaccination via the intranasal route. The goal is to develop a product for the use in the early stage of the disease and which the patient can administrate on his own. This would avoid the traveling of infectious humans to visit a doctor or a hospital. In connection with a telediagnosis SARS-CoV-2_ImmunoJunction can be shipped to the patients home for self-treatment.

Continue Reading